Table 1.
Demographic and clinical characteristics of the participants at baseline.
| Methylfolate, P5P, Methylcobalamin (n = 26) | Placebo (n = 25) | p-Value | Homozygous Minor Allele Carriers (n = 18) | Mixed Allele Carriers (n = 33) | p-Value | |
|---|---|---|---|---|---|---|
| Age, y | 59.2 ± 6.2 | 57.5 ± 9.1 | p = 0.45 | 57.3 ± 7.8 | 59.1 ± 8.9 | p = 0.07 |
| Women, % | 57.7 | 52.0 | p = 0.61 | 60 | 52 | p = 0.21 |
| Body mass index, kg/m2 | 27.5 ± 3.1 | 28.9 ± 3.3 | p = 0.33 | 29.2 ± 3.2 | 27.5 ± 3.6 | p = 0.09 |
| 10-y ASCVD risk, % | 9.9 | 8.5 | p = 0.75 | 10 | 8.5 | p = 0.11 |
| Homocysteine, μmol/L | 18.5 ± 4.1 | 19.1 ± 3.8 | p = 0.81 | 25.1 ± 4.1 | 17.3 ± 3.9 | p < 0.01 |
| Total cholesterol, mg/dL | 180 ± 21 | 185 ± 31 | p = 0.68 | 190 ± 29 | 180 ± 25 | p = 0.08 |
| LDL-C, mg/dL | 125.4 ± 27.2 | 131.7 ± 29.1 | p = 0.57 | 150.1 ± 29.3 | 127.7 ± 26.8 | p < 0.01 |
| HDL-C, mg/dL | 52.4 ± 6.5 | 48.9 ± 4.1 | p = 0.11 | 47.6 ± 4.8 | 52.2 ± 5.8 | p = 0.05 |
| Triglycerides, mg/dL | 159 ± 32 | 148 ± 27 | p = 0.42 | 165 ± 29 | 147 ± 25 | p = 0.18 |
| hsCRP, mg/L | 1.8 ± 0.7 | 2.5 ± 1.1 | p = 0.09 | 2.5 ± 0.9 | 2.0 ± 1.2 | p = 0.23 |